查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1991393

全球抗癌药物市场规模、份额、趋势和成长分析报告（2026-2034年）

Global Oncology Drugs Market Size, Share, Trends & Growth Analysis Report 2026-2034
出版日期: | 出版商: Value Market Research | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计抗癌药物市场规模将从 2025 年的 2,605.4 亿美元成长到 2034 年的 7,064.1 亿美元，2026 年至 2034 年的复合年增长率为 11.72%。

由于癌症发病率上升和医学研究的进步，全球抗癌药物市场正经历显着增长。抗癌药物透过靶向癌细胞或抑制其生长来治疗各种类型的癌症。製药公司和研究机构不断开发创新治疗方法，以提高患者的存活率和治疗效果。

多种因素正在推动抗癌药物市场的成长。全球癌症患者数量的不断增加以及人们对早期诊断意识的提高，都推动了对有效治疗方法的需求。生物技术、免疫疗法和标靶治疗的进步拓宽了治疗选择，使医疗专业人员能够制定个人化的癌症治疗方案。

抗癌药物市场前景依然光明，因为研究不断涌现新的治疗方法。正在进行的临床试验和精准医疗的进步有望进一步改善治疗效果。随着医疗系统扩大先进癌症治疗的覆盖范围，抗癌药物市场预计将稳定成长。

目录

第一章：引言

第二章执行摘要

第三章 市场变数、趋势与框架

  • 市场谱系展望
  • 渗透率和成长前景分析
  • 价值链分析
  • 法律规范
    • 标准与合规性
    • 监管影响分析
  • 市场动态
    • 市场驱动因素
    • 市场限制因素
    • 市场机会
    • 市场挑战
  • 波特五力分析
  • PESTLE分析

第四章：全球抗癌药物市场：依药物类别划分

  • 市场分析、洞察与预测
  • 细胞毒性药物
  • 标靶治疗药物
  • 荷尔蒙药物
  • 其他的

第五章 全球抗癌药物市场：依疗法划分

  • 市场分析、洞察与预测
  • 化疗
  • 标靶治疗
  • 免疫疗法

第六章 全球抗癌药物市场：依适应症划分

  • 市场分析、洞察与预测
  • 肺癌
  • 胃癌
  • 结肠癌
  • 乳癌
  • 摄护腺癌
  • 其他的

第七章 全球抗癌药物市场：以剂型划分

  • 市场分析、洞察与预测
  • 固体的
  • 液体
  • 注射药物

第八章 全球抗癌药物市场：依分销管道划分

  • 市场分析、洞察与预测
  • 医院药房
  • 零售药房
  • 网路药房

第九章 全球抗癌药物市场：依地区划分

  • 区域分析
  • 北美市场分析、洞察与预测
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲市场分析、洞察与预测
    • 英国
    • 法国
    • 德国
    • 义大利
    • 俄罗斯
    • 其他欧洲国家
  • 亚太市场分析、洞察与预测
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 东南亚
    • 其他亚太国家
  • 拉丁美洲市场分析、洞察与预测
    • 巴西
    • 阿根廷
    • 秘鲁
    • 智利
    • 其他拉丁美洲国家
  • 中东和非洲市场分析、洞察与预测
    • 沙乌地阿拉伯
    • UAE
    • 以色列
    • 南非
    • 其他中东和非洲国家

第十章 竞争格局

  • 最新趋势
  • 公司分类
  • 供应链和销售管道合作伙伴（根据现有资讯）
  • 市场占有率和市场定位分析（基于现有资讯）
  • 供应商情况（基于现有资讯）
  • 策略规划

第十一章：公司简介

  • 主要公司的市占率分析
  • 公司简介
    • F. Hoffmann-La Roche Ltd
    • AbbVie Inc
    • Novartis AG
    • Pfizer Inc
    • Bristol Myers Squibb Company
    • GlaxoSmithKline Plc
    • Eli Lilly And Company
    • AstraZeneca
    • Sanofi
    • Bayer AG
    • Merck & Co. Inc
简介目录
Product Code: VMR11213665

The Oncology Drugs Market size is expected to reach USD 706.41 Billion in 2034 from USD 260.54 Billion (2025) growing at a CAGR of 11.72% during 2026-2034.

The global oncology drugs market has experienced significant growth due to the increasing prevalence of cancer and advancements in medical research. Oncology drugs are used to treat various types of cancer by targeting cancer cells or slowing their growth. Pharmaceutical companies and research institutions continue to develop innovative therapies to improve survival rates and treatment outcomes for patients.

Several factors are driving the growth of the oncology drugs market. Rising global cancer cases and growing awareness about early diagnosis have increased demand for effective treatments. Advances in biotechnology, immunotherapy, and targeted therapies have expanded treatment options, allowing healthcare providers to personalize cancer care.

The future outlook for the oncology drugs market remains promising as research continues to produce new treatment approaches. Ongoing clinical trials and advances in precision medicine may further improve treatment effectiveness. As healthcare systems expand access to advanced cancer therapies, the oncology drugs market is expected to grow steadily.

MARKET SEGMENTATION

By Drug Class

  • Cytotoxic Drugs
  • Targeted Drugs
  • Hormonal Drugs
  • Others

By Therapy

  • Chemotherapy
  • Targeted Therapy
  • Immunotherapy

By Indication

  • Lung Cancer
  • Stomach Cancer
  • Colorectal Cancer
  • Breast Cancer
  • Prostate Cancer
  • Others

By Dosage Form

  • Solid
  • Liquid
  • Injectable

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

COMPANIES PROFILED

  • F HoffmannLa Roche Ltd, AbbVie Inc, Novartis AG, Pfizer Inc, Bristol Myers Squibb Company, GlaxoSmithKline plc, Eli Lilly and Company, AstraZeneca, Sanofi, Bayer AG, Merck Co Inc
  • We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definition
  • 1.3. Information Procurement
    • 1.3.1 Information Analysis
    • 1.3.2 Market Formulation & Data Visualization
    • 1.3.3 Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

  • 2.1. Market Snapshot
  • 2.2. Segmental Outlook
  • 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

  • 3.1. Market Lineage Outlook
  • 3.2. Penetration & Growth Prospect Mapping
  • 3.3. Value Chain Analysis
  • 3.4. Regulatory Framework
    • 3.4.1 Standards & Compliance
    • 3.4.2 Regulatory Impact Analysis
  • 3.5. Market Dynamics
    • 3.5.1 Market Drivers
    • 3.5.2 Market Restraints
    • 3.5.3 Market Opportunities
    • 3.5.4 Market Challenges
  • 3.6. Porter's Five Forces Analysis
  • 3.7. PESTLE Analysis

Chapter 4. GLOBAL ONCOLOGY DRUGS MARKET: BY DRUG CLASS 2022-2034 (USD MN)

  • 4.1. Market Analysis, Insights and Forecast Drug Class
  • 4.2. Cytotoxic Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.3. Targeted Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.4. Hormonal Drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 4.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ONCOLOGY DRUGS MARKET: BY THERAPY 2022-2034 (USD MN)

  • 5.1. Market Analysis, Insights and Forecast Therapy
  • 5.2. Chemotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.3. Targeted Therapy Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 5.4. Immunotherapy Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ONCOLOGY DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

  • 6.1. Market Analysis, Insights and Forecast Indication
  • 6.2. Lung Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.3. Stomach Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.4. Colorectal Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.5. Breast Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.6. Prostate Cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 6.7. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ONCOLOGY DRUGS MARKET: BY DOSAGE FORM 2022-2034 (USD MN)

  • 7.1. Market Analysis, Insights and Forecast Dosage Form
  • 7.2. Solid Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.3. Liquid Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 7.4. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL ONCOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

  • 8.1. Market Analysis, Insights and Forecast Distribution Channel
  • 8.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
  • 8.4. Online Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 9. GLOBAL ONCOLOGY DRUGS MARKET: BY REGION 2022-2034 (USD MN)

  • 9.1. Regional Outlook
  • 9.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.2.1 By Drug Class
    • 9.2.2 By Therapy
    • 9.2.3 By Indication
    • 9.2.4 By Dosage Form
    • 9.2.5 By Distribution Channel
    • 9.2.6 United States
    • 9.2.7 Canada
    • 9.2.8 Mexico
  • 9.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.3.1 By Drug Class
    • 9.3.2 By Therapy
    • 9.3.3 By Indication
    • 9.3.4 By Dosage Form
    • 9.3.5 By Distribution Channel
    • 9.3.6 United Kingdom
    • 9.3.7 France
    • 9.3.8 Germany
    • 9.3.9 Italy
    • 9.3.10 Russia
    • 9.3.11 Rest Of Europe
  • 9.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.4.1 By Drug Class
    • 9.4.2 By Therapy
    • 9.4.3 By Indication
    • 9.4.4 By Dosage Form
    • 9.4.5 By Distribution Channel
    • 9.4.6 India
    • 9.4.7 Japan
    • 9.4.8 South Korea
    • 9.4.9 Australia
    • 9.4.10 South East Asia
    • 9.4.11 Rest Of Asia Pacific
  • 9.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.5.1 By Drug Class
    • 9.5.2 By Therapy
    • 9.5.3 By Indication
    • 9.5.4 By Dosage Form
    • 9.5.5 By Distribution Channel
    • 9.5.6 Brazil
    • 9.5.7 Argentina
    • 9.5.8 Peru
    • 9.5.9 Chile
    • 9.5.10 Rest of Latin America
  • 9.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
    • 9.6.1 By Drug Class
    • 9.6.2 By Therapy
    • 9.6.3 By Indication
    • 9.6.4 By Dosage Form
    • 9.6.5 By Distribution Channel
    • 9.6.6 Saudi Arabia
    • 9.6.7 UAE
    • 9.6.8 Israel
    • 9.6.9 South Africa
    • 9.6.10 Rest of the Middle East And Africa

Chapter 10. COMPETITIVE LANDSCAPE

  • 10.1. Recent Developments
  • 10.2. Company Categorization
  • 10.3. Supply Chain & Channel Partners (based on availability)
  • 10.4. Market Share & Positioning Analysis (based on availability)
  • 10.5. Vendor Landscape (based on availability)
  • 10.6. Strategy Mapping

Chapter 11. COMPANY PROFILES OF GLOBAL ONCOLOGY DRUGS INDUSTRY

  • 11.1. Top Companies Market Share Analysis
  • 11.2. Company Profiles
    • 11.2.1 F. Hoffmann-La Roche Ltd
    • 11.2.2 AbbVie Inc
    • 11.2.3 Novartis AG
    • 11.2.4 Pfizer Inc
    • 11.2.5 Bristol Myers Squibb Company
    • 11.2.6 GlaxoSmithKline Plc
    • 11.2.7 Eli Lilly And Company
    • 11.2.8 AstraZeneca
    • 11.2.9 Sanofi
    • 11.2.10 Bayer AG
    • 11.2.11 Merck & Co. Inc